Streetbeat News

Products Services

ANSS

MTLS

Ansys (NASDAQ: ANSS) and Materialise (NASDAQ: MTLS) have announced a strategic partnership to deliver integrated digital solutions to address workflow challenges in the additive manufacturing (AM) industry. The partnership will integrate Ansys Additive Suite into Materialise's data and build preparation tool, Magics. The initial solution, to be previewed at Formnext 2023 and arriving in Q2 2024, will provide a workflow for managing AM industrial projects across industries, including the medical and aerospace sectors.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 2:02 pm

MRK

SLS

SELLAS Life Sciences presented data from a Phase 1/2 trial of Galinpepimut-S in combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting. The combination treatment showed a median overall survival of 18.4 months, compared to 13.8 months in a Keytruda single agent study and 11-14 months with standard of care chemotherapy. The combination also yielded a WT1-specific T-cell immune response and correlated positively in a subset of patients with IFNγ and MIP1β biomarkers.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 2:00 pm

IBM

Riyadh Air and IBM have signed a strategic agreement where IBM Consulting will be the lead systems integrator to support the creation, building, and orchestration of the technology foundation for the digitally native airline. The collaboration aims to position Riyadh Air strategically within the broader ecosystem to offer digital innovations and exceptional experiences for travelers. IBM Consulting will also establish and maintain Riyadh Air's hybrid cloud integration platform.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:59 pm

COMM

STM

CommScope (NASDAQ:COMM) and STMicroelectronics (NYSE:STM) have announced the integration of CommScope's PKIWorks IoT security platform with ST's STM32WB microcontroller unit. This solution simplifies the development and provisioning of secure IoT devices that meet the Connectivity Standards Alliance's Matter standard for security. The collaboration leverages CommScope's experience in integrating cryptographic keys and digital certificates into high-volume manufacturing production and ST's leadership in microcontrollers.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:54 pm

HAL

OIS

Halliburton and Oil States Industries have collaborated to provide innovative deepwater Managed Pressure Drilling solutions. This collaboration will streamline the installation of all aspects of the deepwater Managed Pressure Drilling equipment, control systems, and services.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:52 pm

PLRX

Pliant Therapeutics, Inc. (NASDAQ:PLRX) presented three posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, highlighting PLN-101095, a novel inhibitor of integrins αvβ8 and αvβ1. The company is conducting a Phase 1a trial of PLN-101095 as monotherapy and in combination with pembrolizumab in treatment-resistant patients with advanced or metastatic solid tumors. The inhibitor was also shown to decrease primary tumor growth and improve chemosensitivity in preclinical models of pancreatic ductal adenocarcinoma.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:52 pm

CRSP

CRISPR Therapeutics AG (NYSE:CRSP) shares are trading higher after the company announced preclinical data for its investigational programs for the treatment of cardiovascular disease. The data, set to be presented at the American Heart Association (AHA) Scientific Sessions 2023, covers CTX310 and CTX320, which have been found to reduce ANGPTL3 protein and lipoprotein(a) levels respectively in non-human primates after a single dose.

Portfolio Pulse from Adam Eckert

November 06, 2023 | 1:51 pm

EOLS

Evolus has announced the results from its Phase 2 clinical study evaluating the 'extra-strength' 40U dose for extended duration of Jeuveau. The 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment. The results indicate a similar safety profile to lower dose arms in the study.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:49 pm

BAK

Brazilian petrochemical companies Braskem and Indorama Ventures IOD - Oxiteno have announced a partnership to supply bio-attributed ethylene from renewable sources. The raw material, certified by ISCC, will be used by Oxiteno to create new sustainable solutions. This is the first bio-attributed chemical product produced by Braskem from the certified mass balance approach, which co-processes traditional carbon sources with recycled or renewable components.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:49 pm

AKTX

Akari Therapeutics, Plc (NASDAQ:AKTX) announced that its Chief Scientific Officer will present a poster on the development of PASylated®-Nomacopan for Treatment of Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development conference. The long-acting PAS-nomacopan is in the final stages of pre-clinical development as a potential treatment for GA.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:49 pm